Levi & Korsinsky is investigating potential claims on behalf of purchasers of ViroPharma Inc. (“ViroPharma” or the “Company”) (Nasdaq: VPHM) securities concerning possible violations of federal securities laws. For more information, click here: http://www.zlk.com/viropharma-vphm. The Federal Trade Commission is currently investigating whether ViroPharma engaged in unfair methods of competition in relation to its antibiotic Vancocin. Furthermore, the Food and Drug Administration recently denied ViroPharma’s petition to maintain market exclusivity; by April 11, 2012, four companies began selling authorized generic versions of Vancocin. Since announcing the investigation by the Federal Trade Commission, shares of ViroPharma have fallen over 21 percent. If you own ViroPharma stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com. Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.